HOME > TOP STORIES

TOP STORIES

REGULATORY Chuikyo OKs Drug Pricing Reform Package; 30% Cap Set for “Category I” Companies Allowed to Maintain Full Prices

December 21, 2017
BUSINESS GSK Japan Pres. Kikuchi to Quit after Only 9 Months in Office

December 20, 2017
BUSINESS Gilead Aiming to Develop World’s First NASH Treatment, Hoping for Approval in 2020

December 20, 2017
REGULATORY (Update) Japan to Shave 720 Billion Yen through FY2018 Drug Price Revision

December 19, 2017
REGULATORY Govt to Draw Up “Plan to Strengthen Drug Discovery,” Boosting Budgets to Improve R&D Environment

December 18, 2017
BUSINESS Partnerships Hold Key to Success, Acquisition Not Our Goal: Takeda R&D Head

December 15, 2017
REGULATORY Chuikyo Debate Intermitted as Members Fume at Political Arrangement, New PMP Plan Still Clears Panel with Strings Attached

December 14, 2017
REGULATORY Chuikyo Members Snub Possible Change to 14-Day Prescription Limit

December 13, 2017
BUSINESS Japan Drug Makers Driven by Overseas Sales, See Tepid Revenue at Home: Jiho Tally

December 12, 2017
REGULATORY MHLW Proposes Physician Fee for Proper Antibiotic Use in Children, Aims to Cut Unnecessary Use: Chuikyo

December 11, 2017
BUSINESS AbbVie Hopes Maviret Will Encourage Potential Hep C Patients to Get Treatment: Hepatitis Biz Head

December 11, 2017
REGULATORY Govt’s Modified PMP Plan: “1-Year Cutoff” Extended for 3 Years, 25% of Firms Could Now Maintain Full Prices

December 8, 2017
REGULATORY Easing of Proposed PMP Requirements Likely, Major Focus on “One-Year Cutoff” and “Category I” Scope

December 7, 2017
REGULATORY (Update) NHI-Market Drug Price Gap at 9.1%, 7.1% Regular Price Cut Expected in FY2018

December 6, 2017
REGULATORY NHI-Market Drug Price Gap at 9.1%, 7.1% Regular Price Cut Expected in FY2018

December 6, 2017
REGULATORY Novo’s Semaglutide Stumbles as Panel Puts a Hold on Japan Approval

December 5, 2017
REGULATORY CEFP Members Want Quicker Cuts for Off-Patent Drugs, Pricing Debate Enters Final Stretch

December 4, 2017
BUSINESS Ayumi Looks to Haul in Over 10 Billion Yen from 3 RA Biosimilars: President

December 1, 2017
REGULATORY Japan, US, Europe Trade Groups Forge United Front against Govt PMP Plan, Supportive of Negative List: Chuikyo

November 30, 2017
BUSINESS Japan’s 1st Rituxan Biosimilar to Arrive Soon, Sandoz Confident on Market Acquisition

November 29, 2017

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

More Positions, More Candidates: A Snapshot of Movement in Japan’s Pharma Industry

By Philip Carrigan

Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…